BusinessBeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317By Nasdaq OMXDec 30, 2016, 2:00 PM UTC
BusinessBeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual MeetingBy Nasdaq OMXNov 11, 2016, 12:00 PM UTC
BusinessBeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9By Nasdaq OMXOct 4, 2016, 8:15 PM UTC
